Precision Neuroscience, a brain-computer interface company developing a surface-mounted alternative to implants like Elon Musk's Neuralink, has closed an oversubscribed $250 million Series D round, bringing its total funding to $430 million.
The round was co-led by Pershing Square Inc., the Ackman Oxman Institute and an undisclosed life sciences fund, with participation from Duquesne Family Office, B Capital, ARK Invest, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners, Hitachi Ventures and JSL Health Capital, among others. Bill Ackman, chief executive of Pershing Square, framed the bet as a wager on an emerging category of medicine.
Neurotechnology will be central to the next generation of cures, treatments and rehabilitation.
Bill Ackman, CEO, Pershing Square
A thinner, less invasive approach
Precision's device, called the Layer 7 Cortical Interface, sits on the surface of the brain rather than penetrating it, using electrodes packed onto a film about the size of a postage stamp to record neural activity at high resolution. The company says the design, installed through what it calls a micro-slit incision, is meant to reduce surgical risk relative to penetrating implants while still capturing enough signal to decode intended movement in real time. The device received FDA clearance for 30-day use in 2025, and the underlying technology has been described in peer-reviewed research published in Nature Biomedical Engineering.
The company says the interface has now been used in more than 100 patient procedures across 18 medical institutions, including the University of Pennsylvania, University of Chicago Medicine, Mount Sinai Health System and West Virginia University's Rockefeller Neuroscience Institute. It has also struck a partnership with medical device maker Medtronic to integrate its technology with Medtronic's existing neurosurgical platforms, and built a wholly owned electrode manufacturing facility in Texas to control its own supply chain.
A crowded field chasing the brain
Precision's raise lands amid a wave of investor interest in brain-computer interfaces beyond Neuralink, which has focused on penetrating electrode arrays. Science Corporation, a company founded by former Neuralink president Max Hodak, raised $230 million earlier this year, and Merge Labs, a rival BCI startup, secured $252 million. Chief executive Michael Mager said the next phase of the field will be defined by more than technology alone, pointing to the clinical network, regulatory clearances and manufacturing base Precision has built up as what he expects will separate durable companies from earlier-stage rivals.
Precision said it plans to use the new capital to expand its clinical program, pursue additional FDA review stages for broader use of the Layer 7 device beyond its current 30-day clearance, and build out commercialization infrastructure. The company has not disclosed a timeline for seeking long-term or permanent-use clearance, which would mark the next major regulatory milestone on the path toward wider clinical adoption.
